Opus Genetics Confirms FDA Alignment On Phase 3 Study Design To Evaluate OPGx-LCA5

(RTTNews) - Opus Genetics (IRD) has reached alignment with the FDA in a Type B Rare Disease Evidence Principles meeting on the design of its registrational Phase 3 clinical trial evaluating OPGx-LCA5 for LCA5-associated inherited retinal disease. The company has received the meeting minutes from the Type B meeting confirming several key elements...
2026-07-06 11:30:27